Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 14/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.49 |
| ▸ | CDK2 | P24941 | 14/20 | 0.49 |
| ▸ | CDK7 | P50613 | 14/20 | 0.49 |
| ▸ | CCNH | P51946 | 14/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 14/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 14/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494812 | 1.00 | CCNK (0.49) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL22787807 | 1.00 | CCNK (0.49) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL31460656 | 1.00 | CCNK (0.49) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL28717093 | 1.00 | CCNK (0.49) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL889079 | 0.94 | USP30 (0.53) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL23003229 | 0.93 | CDK2 (0.50) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL23063687 | 0.93 | CDK2 (0.50) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL23003227 | 0.93 | CDK2 (0.50) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL23003217 | 0.89 | CCNA2 (0.60) | CCNKCCNA2CDK2CDK7CCNH | |
| SCHEMBL23003215 | 0.89 | CCNA2 (0.60) | CCNKCCNA2CDK2CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983400-B1 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20220249487-A1 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | PHARMARON, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-3983400-A1 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249487-A1 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | XBP1, HSPA5, ATF4 | CCNK 4676/4885CCNA2 4846/4885CDK2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.